We co-develop & co-market 2 medical devices, perform contract research services, & are developing a proprietary asthma rescue treatment.
We provide drug products & services for the respiratory healthcare market. S-1226™, our lead candidate, is a rescue treatment for acute, severe asthma exacerbations. It fills a major market gap: a short-acting bronchodilator that works via a pathway distinct from Salbutamol, a.k.a. Albuterol. Customers include asthma & chronic obstructive pulmonary disease patients, hospitals & other primary care facilities, large pharma companies & universities.